JAK2 and hepatocellular carcinoma: In another study by Li et al., they reported that diosgenin could inactivate the STAT3 signaling pathway in hepatocellular carcinoma (HCC) cells, by inhibiting intracellular signaling molecules such as c-SRC, JAK1, and JAK2 (Figure 3).